NCT02036632|CompletedPhase 1
Eye Patch Therapy for Central Serous Retinopathy (CSR)
Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy
Loading search results
Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy
Sponsor study identifier
interventional
12
1 country
1
Study Start
November 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2015
Actual (reported)Study Completion
January 2015
Actual (reported)First, this study will investigate the viability of 24-hour eye patching as a potential treatment modality for CSR. Second, this study will assess a potential physiologic explanation for CSR, namely if inhibition of photic stimulation of the diseased retina will aid in ameliorating disease severity and disease duration.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2015
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2012
Date type not reportedThis date has not been verified as actual or estimated.
January 8, 2014
Actual (reported)January 15, 2014
Actual (reported)January 2015
Actual (reported)January 2015
Actual (reported)Change in multi-focal ERG response and macular thickness after 24-hour patch therapy in patients with CSR
This study is a prospective control trial that will compare 24-hour eye patch therapy with the current standard of care in patients with central serous retinopathy (CSR).
24 hours
Change in multi-focal ERG response
24 hours
macular thickness
24 hours
Intervention
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Washington Universtiy School of Medicine
St Louis, Missouri, 63110, United States
Gregory P Van Stavern, MD
Washington University School of Medicine
First Submitted
January 8, 2014
First Posted
January 15, 2014
Study Start
November 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2015
Actual (reported)Eplerenone for Central Serous Chorioretinopathy
Contact the study team to confirm eligibility.
Study Completion
January 2015
Actual (reported)Last Updated
June 3, 2015
Record last verified: 2015-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: